articleTop 1% cited
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
The Lancet Oncology · 2009 · Vol. 11(2) · pp. 121–128
Tetsuya Mitsudomi✉(Aichi Cancer Center)Satoshi Morita(Yokohama City University Medical Center)Yasushi Yatabe(Aichi Cancer Center)Shunichi Negoro(Hyogo Prefectural Cancer Center)Isamu Okamoto(Kindai University)Junji Tsurutani(Kindai University)Takashi Seto(National Hospital Organization Kyushu Cancer Center)Miyako Satouchi(Hyogo Prefectural Cancer Center)Hirohito Tada(Osaka City General Hospital)Tomonori Hirashima(Osaka Prefectural Medical Center)Kazuhiro Asami(National Kinki Chuo Hospital for Chest Disease)Nobuyuki Katakami(Kobe City Medical Center General Hospital)Minoru Takada(Kindai University)Hiroshige Yoshioka(Kurashiki Central Hospital)Kazuhiko Shibata(Kouseiren Takaoka Hospital)Shinzoh Kudoh(Osaka City University)Eiji Shimizu(Tottori University)Hiroshi Saito(Aichi Cancer Center)Shinichi Toyooka(Okayama University)Kazuhiko Nakagawa(Kindai University)Masahiro Fukuoka(Kindai University)
Lung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesHER2/EGFR in Cancer ResearchMedicineGefitinibDocetaxelInternal medicineClinical endpointLung cancerOncologyPopulationEpidermal growth factor receptorProgression-free survival
MeSH terms
DocetaxelGefitinibAgedAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCisplatinFemaleHumansLung NeoplasmsMaleMiddle AgedMutationQuinazolinesTaxoidsErbB Receptors
Funding
- AstraZeneca
- Sanofi
- European Society for Medical Oncology
- Chugai Pharmaceutical
Citations
4,101
FWCI
160.36
field-weighted impact
References
35
Percentile
100%
vs. same field & year
Citations per year
Cited by
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Science Translational Medicine · 2011 · 3,534 citations
The prevalence of <i>EGFR</i> mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Oncotarget · 2016 · 768 citations
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
Journal of Clinical Oncology · 2013 · 3,181 citations
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
The Lancet Oncology · 2015 · 1,573 citations
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2016 · 2,632 citations
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology · 2011 · 4,075 citations
References
Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
Biometrics · 1975 · 2,349 citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine · 2004 · 11,455 citations
Cancer Statistics, 2009
CA A Cancer Journal for Clinicians · 2009 · 9,714 citations
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Journal of Clinical Oncology · 2003 · 2,883 citations
Mutations of the <b> <i>Epidermal Growth Factor Receptor</i> </b> Gene in Lung Cancer
Cancer Research · 2004 · 1,225 citations
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science · 2004 · 9,380 citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
New England Journal of Medicine · 2009 · 8,201 citations
Related articles
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.